PDX Models Market Competitive landscape analysis 2018-2025: The Jackson Laboratory, Champions Oncology, Inc., Oncodesign, WuXi AppTec, Horizon Discovery, Pharmatest Services, MI Bioresearch, Crown Bioscience, Inc., Charles River Laboratories

PDX Models report provides a comprehensive analysis of the PDX Models market sales by showing all the figures in the historic and base year while also showing what the approximate figures are going to be in the forecast years of 2018-2025.

The report also provides with a deep explanation on what the market definition, classifications, applications, and engagements are. By making it clear on how the key players and brands are moving in terms of their sales, import, export and revenue and what their actions are in terms of their recent product launches, their researches, their joint ventures, merges, and accusations.

The report consists with all the company profiles along with the market drivers and restrains with the help of SWOT analysis.

Looking for more information on this market? Get Free sample report @ http://databridgemarketresearch.com/request-a-sample/?dbmr=global-pdx-models-market

Global PDX Models Market is expected to reach USD 275.58 million by 2025 and is projected to register a CAGR of healthy rate in the forecast period 2018 to 2025. The new market report contains data for historic years 2016, the base year of calculation is 2017 and the forecast period is 2018 to 2025.

The global PDX models market highly concentrated to a few big players and rest to local players who cater to domestic markets only. Charles River dominated the PDX models market accounting for a highest market share in 2017, followed by Crown Bioscience Inc. and Champion Oncology, Inc. Other players in this market include are The Jackson Laboratory, Oncodesign, Wuxi Apptec, Horizon Discovery Group plc, Pharma test Services Ltd, Aragen Bioscience (Subsidiary of GVK Biosciences Private Limited), MI Bioresearch Inc., EUROPDX, Creative Animodel, Urolead, Xentech, Hera BioLabs and EPO BERLIN-BUCH GMBH among others.

Charles River:

Founded in 1947 and headquartered in Massachusetts, U.S. Company is mainly focuses on basic research, discovery, safety and efficacy, clinical support and manufacturing of drugs. It deals into different products and services research models and services, discovery services, safety assessment, laboratory sciences, biologics testing solutions, avian vaccine services, QC microbial solutions, training, staffing and operations support. It has its business segments into DSA, RMS and manufacturing. The company has its geographical presence into U.S, Europe, Canada, Asia- Pacific and other.

In October, 2017, Charles river (U.S.) came into in partnership with InSphero AG. (Switzerland) In this the company extended its collection of PDX tumors to Insphero and leverage InSphero’s 3D cell culture technology. This partnership extended company’s pre-clinical service portfolio.
Crown Bioscience Inc.:

Founded in 2006 and headquartered in California, U.S. offers drug discovery and development services to biotech and pharmaceutical partners focusing on oncology and metabolic disease therapeutic areas. The company is completely engaged in providing products and services antibodies, cells, biochemicals, reference standards, recombinat proteins TMA’S, kits and reagents.

The company is based in U.S, U.K, China and Taiwan.

Champion Oncology, Inc.:

Founded in 1985 and has its headquarters in New Jersey, U.S. The company offers end-to-end research and development solutions and services to improve the productivity of oncology drug development. It has its business segment into personalized oncology solutions and Translational oncology solutions. The company is engaged in products and services solutions, products and personalized oncology. It has its presence in U.S. and U.K.

Browse Detailed TOC, Tables and Figures @ http://databridgemarketresearch.com/toc/?dbmr=global-pdx-models-market

Segmentation: Global PDX Models Market

Global PDX Models Market, By Type (Mice Models, Rat Models), Tumor Type (Respiratory Tumor Models, Urological Tumor Models, Gastrointestinal Tumor Models, Hematological Tumor Models, Gynecological Tumor Models, Others), Application (Preclinical Drug Development & Oncology Research, Biomarker Analysis), End User (Contract Research Organization, Academic & Research Institutions, Pharmaceutical & Biotechnology Companies), Geography (North America, Europe, Asia-Pacific, South America, Middle East and Africa) – Industry Trends and Forecast to 2025

Drivers: Global PDX Models Market

Prominent factors driving the growth of this market consist of rising number of pharmaceutical R&D activities in cancer research, advantages offered by PDX models offer compared with the classic approach, rising need for personalized medicine and increasing support for cancer research activities from government and non-government organization.

RISING NUMBER OF PHARMACEUTICAL R&D ACTIVITIES IN CANCER RESEARCH

Cancer is the second most death causing disease in people around the world. According to the study by WHO, there were almost 8.8 million deaths noted due to the cancer in the year 2015 globally. In low- and middle-income countries, 70.0% of deaths are due to cancer. Due to rising cancer prevalence worldwide, the healthcare sector and organizations (both public and private) are investing huge amount of money to carry out various scientific researches to develop novel drugs and technology to treat disease. Government bodies across are investing heavily in research activities for advancements in the field of cancer across the globe. Biotech and pharma companies are accelerating drug development activities in the oncology sector. According to the International Federation of Pharmaceutical Manufacturers & Associations key facts 2017, pharmaceutical industry currently spends over USD 149.8 Billion on R&D activities per year.

Patient Derived Xenograft (PDX) models are majorly used by pharmaceutical and biotechnology companies as models for oncology research. These models provide various aspects of genesis, progression, and clinical course of human cancers. PDX models are generated by transplanting fresh human tumor specimen from a cancer patient into a mouse or rat. Therefore, these models give near accurate assessment of human tumor biology, identification of therapeutic targets, preclinical screening, and evaluation of drugs for various cancers.

According to the article published by THE JACKSON LABORATORY, cancer research is going to get help in improving data sharing and reproducibility. This will be possible through the new minimal information standard for Patient Derived Xenograft (PDX) models, which will make the models easy to find, access, integrate and reuse which are highly used in research.

THE JACKSON LABORATORY is also spending in R&D programs. In 2017, they tripled their investments from previous year. Below mentioned are the investment stats for the amount spent by the company for new research and development.

In 2017, Oncodesign (France), which is a biopharma company dedicated to the precision medicine, invested around 16.15 million USD in 2017 for the research and development activities, which was almost double investment from the previous year.

Is there any query or specific requirements? Ask to our Industry Expert @ https://databridgemarketresearch.com/inquire-before-buying/?dbmr=global-pdx-models-market

About Data Bridge Market Research:

Data Bridge Market Research set forth itself as an unconventional and neoteric Market research and consulting firm with unparalleled level of resilience and integrated approaches. We are determined to unearth the best market opportunities and foster efficient information for your business to thrive in the market. Data Bridge endeavors to provide appropriate solutions to the complex business challenges and initiates an effortless decision-making process.

Contact:
Data Bridge Market Research
Tel: +1-888-387-2818
Email: sopan.gedam@databridgemarketresearch.com

This release was published on openPR.